Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127573841 | 12757384 | 1 | I | 20160527 | 20160919 | 20160919 | PER | US-ALVOGEN-2016-ALVOGEN-024869 | ALVOGEN | 0.00 | F | Y | 75.75000 | KG | 20160919 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127573841 | 12757384 | 1 | PS | CLINDAMYCIN | CLINDAMYCINCLINDAMYCIN PHOSPHATE | 1 | Topical | Y | L23730 | 62800 | 1 | PCT | |||||||
127573841 | 12757384 | 2 | C | DIOVAN | VALSARTAN | 1 | 0 | 4 | MG | TABLET | QD | ||||||||
127573841 | 12757384 | 3 | C | DIOVAN | VALSARTAN | 1 | 0 | 8 | MG | TABLET | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127573841 | 12757384 | 1 | Rosacea |
127573841 | 12757384 | 2 | Hypertension |
127573841 | 12757384 | 3 | Hypertension |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127573841 | 12757384 | Condition aggravated | |
127573841 | 12757384 | Pruritus |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127573841 | 12757384 | 1 | 20160417 | 0 |